



## L. CLINICAL TRIAL AMENDMENT APPROVAL

The CTA Amendment is granted to Sponsor, Clinical Research Organization and/or Principal Investigator once the proposed changes to the protocol and other related documents on the conduct of clinical trial has been approved.

Center/Office/Division	:	Center for Drug Regulation and Research			
Classification	:	Highly Technical			
Type of Transaction	: G2B – Government-to-Businesses				
Who May Avail	no May Avail : All Sponsors, Contract Research Organizations (CROs), Principal Investigators and Im Pharmaceutical Products				
Fees to be Paid	:	AO 50 s. 2001 Php 1,000.00 + 1% LRF			

CHECKLIST OF REQUIREMENTS	WHERE TO SECURE	
AO No. 2020-0010: Regulations on the Conduct of Clinical Trials for Investigational Products  Clinical Trial Amendment Requirements  1. Cover Letter (FDA-CRS Form 2.0)  2. Application Form (Appendix D1)  3. Original Version, corresponding amendments/s and rationale in a tabulated format  4. Supporting Data  5. Proof of Payment	Applicant Company	

CLIENT STEPS	AGENCY ACTION	FEES TO BE PAID	PROCESSING TIME	PERSON RESPONSIBLE
Secure a schedule of appointment / submission to FDAC	Sends the scheduled date of submission for pre-assessment	None		FDAC Personnel





2. E-mail submission: Submits the application for pre- assessment through fdac.letters.cdrr@fda.gov.ph  For COVID-19 related applications, sends through clinicalresearch@fda.gov.ph	2. Pre-assesses the completeness of the application.  If the application is acceptable, informs the client of the result of the pre-assessment and instructs the client to proceed with payment.  If the application did not satisfactorily pass the pre-assessment, advises client to secure a new appointment schedule for pre-assessment and new Document Tracking Number (DTN).	None		CDRR Personnel
<ul> <li>3. For accepted applications,</li> <li>pays the required fee through any of the following:</li> <li>FDA Cashier</li> <li>BANCNET</li> <li>Landbank OnColl</li> </ul> Sends proof of payment to the FDAC.	Upon receipt of the proof of payment, endorses the application to CDRR for evaluation.	See Table Above	Day 1 1 working day	FDA Cashier/ Landbank FDAC Personnel
	Receives the application from FDAC and encodes/updates the database	None	Day <u>2</u> <u>1</u> working day	Center for Drug Regulation and Research (CDRR) – Central Receiving and Releasing (CRR) Unit
	Decks/Assigns the application to the assigned evaluator	None	Day <u>2</u> <u>1</u> working day	CDRR Director/ CRR Unit Personnel





If an electronic notice of deficiencies (E- NOD) was issued by the evaluator, submits complete compliance documents to the evaluator	Evaluates the application according to requirements and prescribed standards  *Any minor deficiencies/ clarifications will be communicated to the clients through electronic communication	None	Day <u>3-15</u> <u>13</u> working days	Food-Drug Regulation Officer (FDRO) I/II (Junior Evaluator)/ FDRO III (Senior Evaluator)
	Reviews the evaluated application bearing the recommendation of the evaluator	None	Day <u>16-17</u> <u>2</u> working days	Clinical Research Section Supervis
	8. Prints the final response and transmittal, and forwards it to the Product Research and Standards Development Division (PRSDD) Chief	None	Day <u>17</u> <u>1</u> working day	FDRO I/II/III
	Checks and recommends the decision of the evaluator/s by affixing initial/signature	None	Day 1 <u>8</u> 1 working day (per batch of applications)	PRSDD Chief
	10. Signs and approves the final decision	None	Day <u>19</u> <u>1</u> working day (per batch of	CDRR Director
	11. Encodes/Updates the Database and Endorses the final output document to the FDAC Releasing Section	None	Day <u>20</u> <u>1</u> working day (per batch of applications)	CDRR-CRR Unit <i>Personnel</i>





	TOTAL:	PHP 1,010.00	20 working days	
4. Receives the letter	12. Releases the letter to the client	None	Day <u>20</u> <u>1</u> working day	FDAC Releasing Section Personnel